Statistics from Altmetric.com
Editor—Chronic progressive external ophthalmoplegia (CPEO) is a common clinical manifestation of mitochondrial cytopathies characterised by ophthalmoplegia and ptosis.1 Approximately two-thirds of CPEO patients harbour a large, heteroplasmic, mitochondrial DNA (mtDNA) deletion.2 Some other CPEO patients carry a point mutation in the mitochondrial tRNA genes. Twelve point mutations in six mitochondrial tRNA genes have been reported to date in association with CPEO (Mitomap at http://www.gen.emory.edu/mitomap.html). Among the 12 mutations, 5703C→T in the tRNAAsn gene has been functionally characterised.3 Here we report functional analysis of 5877G→A in tRNATyr identified in a patient with CPEO4 using ρ0 cells that lack mtDNA.
A 45 year old woman had moderate degrees of ptosis, external ophthalmoplegia, and proximal muscle weakness from the age of 28. She had no sensorineural hearing loss, ataxia, pigmentary retinopathy, hypogonadism, or mental retardation. She had episodic diarrhoea of unknown aetiology. An ECG showed atrioventricular conduction block, while EEG, brain CT, and brain MRI showed no abnormalities. An exercise loading test of 15 watts for 15 minutes on a bicycle ergometer5 raised her serum lactate from 6.9 mg/dl to 24.0 mg/dl (normal, less than 18.0 mg/dl), and her serum pyruvate from 0.6 mg/dl to 1.4 mg/dl (normal, less than 1.3 mg/dl), thereby increasing the lactate to pyruvate ratio from 10.7 to 17.1 (normal, less than 13.8). A biopsy specimen obtained from the biceps brachii showed 4.0% ragged red fibres and 0.7% cytochrome coxidase negative fibres.
Mutation analysis of muscle mtDNA was briefly described previously (patient 2 in Ozawa et al 4). Determination of the entire mtDNA sequence showed 34 nucleotide changes; 33 were homoplasmic and were observed in 274 controls with variable frequencies. A 5877G→A transition in the tRNATyrgene was heteroplasmic and unique to the patient. The ratios of mutant to wild type mtDNA were 73% in skeletal muscle and 0.7% in blood (fig1B). The 5877G→A mutation is located in the DHU loop of the tRNATyr gene (fig 1A). The 5877G base pairs with 5905C in the variable loop (circle in fig 1A) to form the L shaped tertiary structure of the tRNA molecule.6 The 5877G is conserved in 29 of 43 species or in 25 of 28 vertebrates (alignment not shown). The 5877G→A mutation has not been reported in other patients with mitochondrial cytopathies (Mitomap).
Restriction enzyme analysis of blood and umbilical cord DNA of family members showed that the deceased mother, who had ptosis, carried 5877G→A and that two asymptomatic children (a 21 year old son and 19 year old daughter) harbour 5877G→A in peripheral blood and umbilical cord (fig 1B). The patient developed ptosis at the age of 28 and the children may be too young to show any symptoms. Alternatively, the ratio of mutant mtDNA in muscle may be less in the children than in the patient. The children had no increase in resting serum lactate. Two asymptomatic paternal half sisters (aged 60 and 59 years) do not carry 5877G→A (fig 1B). Photographs showed that the maternal grandmother also had ptosis, but her DNA was not available.
To characterise the functional consequences of 5877G→A, we transformed ρ0 cells with patient's skin fibroblasts as described elsewhere.7 We obtained four distinct cybrid clones, H35, H25, H63, and H11, harbouring 0, 3, 39, and 23% of mutant mtDNA, respectively. We measured the oxygen consumption as an indicator for the mitochondrial respiratory chain functions, using a Clark type oxygen electrode. The H35 clone showed the highest oxygen consumption and the H11 clone the lowest (fig 2A). We next measured the viability of cybrids under 95% oxygen on days 3 and 4 by staining cells with 0.15% trypan blue, because we assumed that mutant mtDNA increases the leakage of reactive oxygen species, which in turn exerts cytotoxic effects leading to cell death.8 Even normal mitochondria convert approximately 1-5% of oxygen into the reactive oxygen species, which results in degeneration of proteins, lipids, and nucleic acids.9 Similar to the oxygen consumption analysis, H35 showed the highest viability rate and H11 the lowest (fig 2B). Although H63 harboured a higher ratio of mutant mtDNA than H11, H63 showed higher oxygen consumption and higher viability rate than H11. This may be because of the difference in the intracellular distribution of mutant mtDNA or in the total number of transformed mtDNA.
A previously characterised 5703C→T mutation at the anticodon stem of tRNAAsn destabilises the tRNA secondary or tertiary structure and decreases steady state levels of tRNAAsn.3 The present 5877G→A mutation in tRNATyr alters an essential residue to form the L shaped tertiary structure of tRNA.6 Similarly, seven out of the 11 other CPEO associated point mutations (Mitomap) are at the tRNA stems and probably destabilise the tRNA structure. However, four other mutations are at the tRNA loops and their effects on the tRNA structure remain unknown.
The 5877G→A mutation exerts deleterious effects even at 23% of mutant mtDNA, whereas more than 90% of mutant mtDNA is required to show pathogenicity of 3243A→G in tRNA Leu(UUR),10 which is primarily associated with MELAS.11 Hao and Moraes3 proposed that null or near null mtDNA mutations are associated with muscle pathologies, as exemplified in 5703C→T in tRNAAsn and in mtDNA deletions. On the other hand, less severe mtDNA mutations are associated with central nervous system symptoms, as in the MELAS and MERRF associated mutations.10 That low levels of mutant mtDNA decrease oxygen consumption and compromise cell viability under 95% oxygen in the current studies further supports their hypothesis on phenotype-genotype correlation of mtDNA mutations.
This work was supported in part by the Grants in Aid for General Scientific Research (62570128) to MT from the Ministry of Education, Science, and Culture of Japan, and the Research Grant (11B-1) for Nervous and Mental Disorders to KS from the Ministry of Health and Welfare of Japan. We presented part of the present study in a review article (Nippon Rinsho1997;55:3265-9).
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.